Pancreatic Cancer Market Forecasts to 2030 – Global Analysis By Type (Pancreatic Neuroendocrine Tumors and Pancreatic Adenocarcinoma), Treatment Type (Immunotherapy, Surgery, Chemotherapy, Hormone Therapy, Targeted Drug Therapy, Radiation Therapy and Othe

Pancreatic Cancer Market Forecasts to 2030 – Global Analysis By Type (Pancreatic Neuroendocrine Tumors and Pancreatic Adenocarcinoma), Treatment Type (Immunotherapy, Surgery, Chemotherapy, Hormone Therapy, Targeted Drug Therapy, Radiation Therapy and Other Treatment Types), Diagnosis, Stage of Cancer, Affected Area, End User and By Geography

According to Stratistics MRC, the Global Pancreatic Cancer Market is accounted for $2.9 billion in 2023 and is expected to reach $8.1 billion by 2030 growing at a CAGR of 15.6% during the forecast period. Pancreatic cancer is a malignant neoplasm affecting the pancreas, a crucial organ located behind the stomach. This type of cancer occurs when cells in the pancreas undergo uncontrolled growth and division, forming a tumor. It can spread rapidly to nearby organs and distant sites in the body, making it challenging to treat. Symptoms of pancreatic cancer may include abdominal pain, weight loss, jaundice, digestive problems, and fatigue.

According to o the America’s Cancer Society for pancreatic cancer, about 64,050 people will be diagnosed with pancreatic cancer in 2023 and estimation of around 50,550 people will die of pancreatic cancer.

Market Dynamics:

Driver:

Rising incidence of pancreatic cancer

There is a rapid increase in the prevalence of cancer cases, and its growth is driven by factors such as an unhealthy diet, physical inactivity, tobacco and alcohol consumption, air pollution, and physical inactivity. The incidence of cancer cases rises dramatically due to the buildup of cancer cases specific to age and the less effective repair mechanisms that become less effective as the person grows older. Furthermore, there are a growing number of chronic infections that are thought to be risk factors for cancer cases, primarily in countries with low or middle incomes. Therefore, rising incidence is a significant factor propelling market demand.

Restraint:

High treatment costs

High treatment costs pose a significant threat to the pancreatic cancer market. Treatment for pancreatic cancer may be expensive and include radiation therapy, chemotherapy, surgery, and supportive care. Patients may find it difficult to afford or obtain treatment due to its high cost, which may negatively impact their capacity to get timely and effective care. However, the financial burden of treatment can deter patients from seeking necessary medical attention or opting for recommended treatment options. This can lead to delays in diagnosis, suboptimal treatment choices, and poorer treatment outcomes.

Opportunity:

Rise in clinical research

The increase in epidemiologic and basic clinical research is leading to improved prevention, diagnosis, and treatment. Researchers are continuously unravelling the complex molecular and genetic mechanisms underlying pancreatic cancer, paving the way for innovative treatment modalities. Moreover, the exploration of new drug targets, biomarkers, and personalized medicine strategies is a testament to the evolving landscape of pancreatic cancer research. Therefore, a rise in clinical research is a good opportunity for pancreatic cancer treatment.

Threat:

Side effects

Pancreatic cancer treatments have various side effects during and after the treatment, depending on the patient. The most common cancer treatment, chemotherapy, works to kill cancerous cells in the pancreas but also eliminates healthy cells from the body, which has a negative impact on health and the recurrence of side effects in patients. Additionally, there are certain adverse effects from radiation therapy used to treat cancer, like skin reddening, nausea, and appetite loss. In rare instances, even diarrhoea is caused by radiation exposure. Therefore, the side effects of pancreatic cancer treatment impede the growth of the market.

Covid-19 Impact

The COVID-19 pandemic has significantly impacted the pancreatic cancer market. The pandemic caused delays in cancer screenings, diagnoses, and treatment plans, among other routine healthcare services. Patients with pancreatic cancer faced hurdles in accessing timely medical care due to restrictions, reallocation of resources, and a shift in healthcare priorities toward managing the pandemic. Moreover, clinical trials and research activities were also affected, which slowed down the progress of new treatment modalities and therapeutic advancements.

The chemotherapy segment is expected to be the largest during the forecast period

The chemotherapy segment is estimated to hold the largest share. Chemotherapy is becoming increasingly common due to benefits like stopping cancer from spreading, killing cancer cells, slowing the growth of the disease, and using strong chemicals to kill rapidly growing cells. Moreover, chemotherapy is used in any stage of pancreatic cancer to kill the cancer cells, and the drugs are administered in cycles with an alternating period of diagnosis and recovery. Additionally, chemotherapy for pancreatic cancer can be given during surgery or in conjunction with radiation therapy.

The clinics segment is expected to have the highest CAGR during the forecast period

The clinics segment is anticipated to have lucrative growth during the forecast period. The primary drivers of the growth of specialty clinics or cancer centers are genuine treatment combined with high-quality services. The availability of clinical staff members is a benefit of specialty clinics because oncologists and medical professionals share the same entity and specialization, and the patient can easily and affordably receive a diagnosis and treatment. Specialty clinics only offer specialized types of medicine, such as cancer centers for cancer patients, making it easier to manage insurance, patient scheduling, and access to the most recent advancements in cancer treatment.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. The region has a sizable and quickly expanding population, which raises the prevalence of pancreatic cancer cases. The prevalence of risk factors such as smoking, obesity, and diabetes further adds to the disease burden in this region. Furthermore, access to cancer treatment and the quality of healthcare infrastructure have both improved in the Asia-Pacific region. The availability of advanced diagnostic technologies, including imaging modalities and molecular testing, has enhanced the early detection and diagnosis of pancreatic cancer. This has led to improved patient outcomes and an increased demand for diagnostic services in this region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. North America has a high prevalence of pancreatic cancer, making it a crucial region for research, diagnosis, and treatment advancements. Considerable progress has been made in the understanding of the disease and the development of targeted therapies due to the region's strong research infrastructure and funding opportunities. Furthermore, North America has a well-established healthcare system that provides access to specialized healthcare services and advanced treatment options.

Key players in the market

Some of the key players in the Pancreatic Cancer Market include Diffusion Pharmaceuticals, Novartis International AG, Amgen, Inc., Pharmacyte Biotech Inc., Polaris Pharmaceuticals, Inc., Clovis Oncology, OncoGenex Pharmaceuticals Inc., Oncolytics Biotech, Sun BioPharma, Inc., Eli Lilly and Company, Midatech Pharma PLC, F. Hoffmann-La Roche AG and Celgene Corporation.

Key Developments:

In Oct 2023, Sun Pharma and Zydus Life sciences announced that they have entered into a licensing agreement to co-market Desidustat, an oral treatment for anaemia associated with Chronic Kidney Disease (CKD) in India.

In Jan 2022, Novartis announced collaboration with Alnylam to leverage Alnylam’s proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for Bio Medical Research, potentially leading to development of a treatment designed to promote the re growth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.

Types Covered:
• Pancreatic Neuroendocrine Tumors
• Pancreatic Adenocarcinoma

Treatment Types Covered:
• Immunotherapy
• Surgery
• Chemotherapy
• Hormone Therapy
• Targeted Drug Therapy
• Radiation Therapy
• Other Treatment Types

Diagnosis Covered:
• Computerized Tomography (CT) Scans
• Blood Test
• Positron Emission Tomography (PET) Scans
• Ultrasound
• Magnetic Resonance Imaging (MRI)
• Biopsy
• Other Diagnosis

Stage of Cancers Covered:
• Early Stage
• Locally Advanced
• Metastatic

Affected Areas Covered:
• Endocrine
• Exocrine

End Users Covered:
• Hospitals
• Diagnostic Laboratories
• Research Laboratories
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements